Comparative Pharmacology
Head-to-head clinical analysis: BIVALIRUDIN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIVALIRUDIN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bivalirudin is a direct thrombin inhibitor that binds specifically and reversibly to both free and clot-bound thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin, platelet activation, and clot formation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous bolus of 0.75 mg/kg followed by continuous infusion at 1.75 mg/kg/hour for the duration of percutaneous coronary intervention (PCI). For heparin-induced thrombocytopenia (HIT) patients undergoing PCI, the same dosing is used. For HIT patients without PCI, alternative dosing may be considered.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
The terminal elimination half-life in patients with normal renal function is approximately 25-35 minutes (mean 25 minutes). In patients with moderate-to-severe renal impairment (CrCl <30 mL/min), half-life can be prolonged to 1-3 hours. Clinical context: short half-life allows for rapid reversal upon discontinuation; however, dose adjustment is required in renal impairment.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal excretion of unchanged drug accounts for approximately 20-25% of the administered dose; the remainder undergoes hepatic metabolism and proteolysis, with subsequent renal and biliary elimination of metabolites. Fecal excretion is minimal (<5%).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte